Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on March 1, 2017. The filing serves to announce the company's financial results for the fourth quarter and the full year ended December 31, 2016.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the period ended December 31, 2016.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release dated March 1, 2017) for specific revenue, net income, and cash flow figures.
- Verify the company's name change status, as the filing header lists "Pacira Pharmaceuticals, Inc." while the request metadata indicates "Pacira Biosciences, Inc."
- Confirm the specific details of the fourth quarter and full-year 2016 performance in the attached press release.